Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results CC transcript Filed Chapter 11 Director departure
|
BAXANO SURGICAL, INC. (BAXS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/05/2014 |
8-K
| Quarterly results |
05/08/2014 |
8-K
| Quarterly results |
08/12/2013 |
8-K
| Quarterly results |
05/10/2013 |
8-K
| Quarterly results |
03/05/2013 |
8-K
| Quarterly results
Docs:
|
"Agreement and Plan of Merger, among TranS1 Inc., RacerX Acquisition Corp., Baxano, Inc., and Sumeet Jain and David Schulte as Securityholder Representatives",
"List of Schedules Omitted from Agreement and Plan of Merger included as Exhibit 2.1 above",
"Form of Securities Purchase Agreement, between TranS1 Inc. and the investors identified on the signature pages thereto",
"TranS1 Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended December 31, Twelve Months Ended December 31, 2012 2011 2012 2011 Revenue $ 4,129 $ 3,990 $ 14,570 $ 19,153 Cost of revenue 1,562 1,042 4,309 4,555 Gross profit 2,567 2,948 10,261 14,598 Operating expenses: Research and development 1,520 1,350 5,457 5,191 Sales and marketing 4,925 4,906 20,049 21,561 General and administrative 1,510 1,368 6,172 5,890 Charges related to U.S. Government settlement 6,583 235 8,324 235 Total operating expenses 14,538 7,859 40,002 32,877 Operating loss Other income , net 6 Net loss $ $ $ $ Other comprehensive loss: Foreign currency translation adjustments - 40 1 42 Comprehensive loss $ $ $ $ Net loss per common share - basic and diluted $ $ $ $ Weighted average commo...",
"Conference call transcript",
"Joseph P. Slattery, 919-825-0868 Executive Vice-President and Chief Financial Officer" |
|
11/13/2012 |
8-K
| Quarterly results |
08/15/2012 |
8-K
| Quarterly results
Docs:
|
"TranS1 Inc. Consolidated Statements of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2012 2011 2012 2011 Revenue $ 3,460 $ 5,337 $ 7,243 $ 10,467 Cost of revenue 912 1,173 1,909 2,469 Gross profit 2,548 4,164 5,334 7,998 Operating expenses: 73.6 % 78.0 % 73.6 % 76.4 % Research and development 1,244 1,212 2,577 2,794 Sales and marketing 5,371 5,671 10,670 12,054 General and administrative 2,224 1,610 4,106 3,223 Total operating expenses 8,839 8,493 17,353 18,071 Operating loss Other income , net 20 38 Net loss $ $ $ $ Other comprehensive income : Foreign currency translation adjustments - 6 - 14 Comprehensive loss $ $ $ $ Net loss per common share - basic and diluted $ $ $ $ Weighted average common shares outstanding - basic and diluted 27,255 20...",
"Conference call transcript" |
|
05/11/2012 |
8-K
| Quarterly results |
03/13/2012 |
8-K
| Form 8-K - Current report |
11/04/2011 |
8-K
| Quarterly results |
08/15/2011 |
8-K
| Form 8-K - Current report |
05/17/2011 |
8-K
| Quarterly results |
02/25/2011 |
8-K
| Form 8-K - Current report |
11/15/2010 |
8-K
| Quarterly results |
08/09/2010 |
8-K
| Form 8-K - Current report |
05/06/2010 |
8-K
| Quarterly results |
02/25/2010 |
8-K
| Form 8-K - Current report |
11/03/2009 |
8-K
| Quarterly results |
08/03/2009 |
8-K
| Form 8-K - Current report |
04/30/2009 |
8-K
| Form 8-K -- Current report |
02/25/2009 |
8-K
| Form 8-K -- Current report |
11/03/2008 |
8-K
| Quarterly results |
08/04/2008 |
8-K
| Quarterly results |
05/05/2008 |
8-K
| Quarterly results |
02/26/2008 |
8-K
| Quarterly results |
11/09/2007 |
8-K
| Quarterly results |
|
|